-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Biogen, Raises Price Target to $250

Benzinga·10/21/2026 13:55:08
TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $225 to $250.